Unknown

Dataset Information

0

Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.


ABSTRACT:

Background?

Direct oral anticoagulants (DOAC) are an attractive alternative over vitamin K antagonists. They have several advantages in primary and secondary prevention of thromboembolisms due to atrial fibrillation, as well as in prevention and treatment of thromboembolic venous disease. They have fast onset action, do not need laboratory controls in patients with normal renal function, and they have practically no interference with the patient's diet or medications. The strongest objection to their use was the lack of reversal agents that could be used in case of life-threatening haemorrhage or the need for emergency surgery. Dabigatran was the first DOAC to have its own specific reversal agent: idarucizumab, a monoclonal antibody.

Case summary?

We report here the case of a patient undergoing treatment with dabigatran that suffered an expansive subdural haematoma secondary to a cranial injury. The condition was life-threatening and required emergency surgery. Anticoagulation was successfully reversed with idarucizumab.

Discussion?

Emergency surgery in patients in treatment with DOAC is associated with an increased risk of bleeding. With the use of a specific antidote to block the action of the anticoagulant, as in the case of idarucizumab with dabigatran, the risk of complications during and after emergency surgery is reduced. This is the first case report with which the successful use of idarucizumab in Latin America is documented.

SUBMITTER: Izaguirre Avila R 

PROVIDER: S-EPMC6601192 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.

Izaguirre Ávila Raúl R   Bahena López José Eduardo JE   Cortina de la Rosa Evelyn E   Hernández Márquez Miguel Ángel MÁ  

European heart journal. Case reports 20190601 2


<h4>Background</h4>Direct oral anticoagulants (DOAC) are an attractive alternative over vitamin K antagonists. They have several advantages in primary and secondary prevention of thromboembolisms due to atrial fibrillation, as well as in prevention and treatment of thromboembolic venous disease. They have fast onset action, do not need laboratory controls in patients with normal renal function, and they have practically no interference with the patient's diet or medications. The strongest object  ...[more]

Similar Datasets

| S-EPMC7081017 | biostudies-literature
| S-EPMC6852568 | biostudies-literature
| S-EPMC4876800 | biostudies-literature
| S-EPMC4945814 | biostudies-literature
| S-EPMC7237558 | biostudies-literature
| S-EPMC10704007 | biostudies-literature
| S-EPMC5222901 | biostudies-other
| S-EPMC5121568 | biostudies-literature
| S-EPMC8173663 | biostudies-literature
| S-EPMC6458174 | biostudies-literature